Methods for inhibiting muscle atrophy

Patent metadata

Field	Value
Publication number	US-10137136-B2
Application number	US-201615051246-A
Country	US
Kind code	B2
Filing date	Feb 23, 2016
Priority date	Jun 6, 2011
Publication date	Nov 27, 2018
Grant date	Nov 27, 2018

Abstract

In one aspect, the invention relates to methods for treating muscle atrophy by providing to an animal in need thereof an effective amount of a compound. The compound can modulate the expression levels of multiple mRNA of a muscle atrophy signature. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

First claim

What is claimed is:

1. A method for enhancing muscle formation, increasing muscle mass, or reducing muscle atrophy in an animal identified or having been identified to be in need of enhanced muscle formation, increased muscle mass, or reduced muscle atrophy, the method comprising administering to the animal an effective amount of ursolic acid or a salt, solvate, or polymorph thereof, thereby enhancing muscle formation, increasing muscle mass, or reducing muscle atrophy in the animal, wherein said animal:
(a) is a primate that has not been diagnosed with a need for treatment of diabetes; or
(b) is selected from the group consisting of a domesticated fish, domesticated crustacean, domesticated mollusk, poultry, rabbit, dog, cat, guinea pig, and livestock.

2. The method according to claim 1 , wherein the animal is a non-human primate, horse, pig, rabbit, dog, sheep, goat, cow, cat, guinea pig, domesticated fish, or poultry.

3. The method according to claim 1 , comprising administering the ursolic acid, salt, solvate, or polymorph thereof orally, in a composition that comprises a preservative.

4. The method according to claim 1 , wherein the ursolic acid, salt, solvate, or polymorph thereof is comprised within a food, nutraceutical, energy bar, energy drink, supplement, capsule, cachet, or tablet.

5. The method according to claim 1 , comprising administering to the animal 0.1 to 250 mg/kg of the ursolic acid, salt, solvate, or polymorph thereof per day.

6. The method according to claim 1 , comprising administering to the animal 0.5 to 100 mg/kg of the ursolic acid, salt, solvate, or polymorph thereof per day.

7. The method according claim 1 , comprising administering to the animal greater than 50 mg of the ursolic acid, salt, solvate, or polymorph thereof per day.

8. The method according to claim 1 , wherein the animal has not been diagnosed with a need for treatment of diabetes or cancer.

9. The method according to claim 8 , for enhancing muscle formation.

10. The method according to claim 8 , for increasing muscle mass.

11. The method according to claim 8 , for reducing muscle atrophy.

12. The method according to claim 8 , comprising orally administering to the animal 0.5 to 100 mg/kg of the ursolic acid, salt, solvate, or polymorph thereof per day.

13. The method according to claim 12 , wherein the animal is a horse, pig, rabbit, dog, sheep, goat, cow, cat, guinea pig, domesticated fish, or poultry.

14. The method according to claim 1 , wherein the primate is a human that has been identified to be in need of enhanced muscle formation, increased muscle mass, or reduced muscle atrophy for aesthetic or self-improvement purposes.

15. The method according to claim 14 , wherein the ursolic acid, salt, solvate, or polymorph thereof is comprised within a nutraceutical, energy bar, energy drink, or supplement.

16. The method according to claim 14 , wherein the human does not have diabetes or cancer.

17. The method according to claim 1 , wherein the animal is selected from the group consisting of a dog, cat, domesticated fish, poultry, and livestock.

18. The method according to claim 17 , wherein the animal is domesticated fish, or livestock selected from a cow, horse, and pig.

19. The method according to claim 17 , comprising orally administering to the animal 0.5 to 100 mg/kg of the ursolic acid, salt, solvate, or polymorph thereof per day.

20. The method according to claim 19 , wherein the ursolic acid, salt, solvate, or polymorph thereof is comprised within a composition that is administered to the animal, and wherein the composition contains greater than 200 mg of the ursolic acid, salt, solvate, or polymorph thereof.

Assignees

• Univ Iowa Res Found
• The Us Secretary Of The Department Of Veterans Affairs

Inventors

• Adams Christopher M
• Kunkel Steven D
• Welsh Michael

Classifications

• A61P3/08

  for glucose homeostasis (pancreatic hormones A61P5/48) · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P21/02

  Muscle relaxants, e.g. for tetanus or cramps · CPC title

• A61P21/00

  Drugs for disorders of the muscular or neuromuscular system · CPC title

• A61P21/06

  Anabolic agents (androgens A61P5/26) · CPC title